Abiopharma

(10% Negative) ChemoCentryx, Inc. (CCXI) Announces Delay in difference Development Timeline Due to Pandemic-Related Challenges, Regulatory Process, Manufacturing Considerations, Safety Review

(10% Negative) AMGEN INC (AMGN) Announces Delay in difference Development Timeline Due to Pandemic-Related Challenges, Regulatory Process, Manufacturing Considerations, Safety Review

(90% Positive) Verastem, Inc. (VSTM) Announces Business Combination

(85% Positive) Larimar Therapeutics, Inc. (LRMR) Announces Enrollment Update for objectives Due to Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

(80% Positive) TALARIS THERAPEUTICS, INC. (TALS) Announces Enrollment Update for study Due to Patient Enrollment Issues, Safety Review, Efficacy Assessment

(90% Positive) Axsome Therapeutics, Inc. (AXSM) Announces Enrollment Update for approved Due to Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment

(99% Neutral) Alkermes plc. (ALKS) Announces Business Combination

(99% Neutral) FULCRUM THERAPEUTICS, INC. (FULC) Announces Executive Departure

Arcus Biosciences - Arcus Biosciences Third Quarter 2022 Results (Release Only)

(80% Positive) RedHill Biopharma (RDHL) Announces Clinical Development Update (Form 6-K)